The pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during the forecast period. The growth of the pharmaceutical drug delivery market can largely be attributed to factors such as the rising prevalence of chronic diseases, growing biologics market, increasing R&D investments, and technological advancements & new product launches.
On the other hand, the risk of needlestick injuries and the increased pricing pressure is expected to limit the market growth to some extent in the coming years.
To know about the assumptions considered for the study download the pdf brochure
The global pharmaceutical drug delivery market is highly competitive, with many leading market players based in developed countries. The prominent players in this market are Johnson & Johnson (US), Novartis International AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (US), Bayer AG (Germany), Antares Pharma, Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), 3M (US), Merck & Co., Inc. (US), Sanofi (France), Amgen, Inc. (US), AbbVie Inc. (US), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca plc. (UK), Eli Lilly and Company (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol-Myers Squibb (US), Gerresheimer AG (Germany), Boston Scientific Corporation (US), Nimbus Therapeutics (US), Kite Pharma (US), and IDEAYA Biosciences, Inc. (US). However, several smaller players have emerged from niche markets in the past few years, competing with global players based on price and product offerings. Due to intense competition in the market, major market players are increasingly focusing on expanding their geographic presence into high-growth emerging markets and strengthening their technological competitiveness by acquiring smaller players with the desired technological capabilities or geographical presence.
The leading position of Johnson & Johnson (J&J) (US) in this market is due to its strong brand recognition. The company focuses on adopting organic as well as inorganic growth strategies to expand its presence in the drug delivery technology market. For instance, in April 2020, Janssen Pharmaceutical Companies collaborated with Emergent BioSolutions to support the manufacturing and expansion of its investigational COVID-19 vaccine. Janssen aims to supply over a billion doses of their vaccine worldwide. In January 2019, Janssen (J&J) collaborated with MeiraGTx Holdings (US) to develop, manufacture, and commercialize its clinical-stage inherited retinal disease drug portfolio.
F. Hoffmann-La Roche Ltd. (Switzerland) was the third-largest player in the pharmaceutical drug delivery market. In order to strengthen its position in the pharmaceutical drug delivery market, the company focuses on receiving approvals for various therapeutic applications. Some of its recent product approvals include Tecentriq (atezolizumab) for the treatment of Liver Cancer, metastatic non-squamous non-small cell lung cancer (NSCLC); Venclexta (venetoclax) for the treatment of people with newly-diagnosed acute myeloid leukemia (AML), Chronic lymphocytic leukemia; Polivy for Lymphoma, and Xofluza (baloxavir marboxil) for the treatment of flu (influenza).
Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE